News & Updates

Use of biologics provides clinical benefits in patients with chronic, refractory inflammatory conditions of the pouch, with no new safety signals observed, reports a study. Moreover, infliximab appears more effective than adalimumab and vedolizumab for chronic antibiotic-refractory pouchitis (CARP).

Drinking coconut water may help individuals with mild-to-moderate ulcerative colitis achieve remission, as shown in a study.

Individuals who have donated a kidney appear to be at increased risk of vertebral fractures, according to a study.

In the treatment of chronic rhinosinusitis (CRS), exhalation delivery system with fluticasone (EDS-FLU) provides relief from symptoms while reducing intrasinus disease and the incidence of acute exacerbations, regardless of the presence of polyps, as shown in the phase III trials ReOpen1 and ReOpen2.

A two-sample Mendelian randomization (MR) study has found no causal effect of plasma omega-3 polyunsaturated fatty acids (PUFAs) on sarcopenia-related traits, such as lean mass, grip strength, and walking pace.

Combining the programmed cell death ligand 1 (PDL-1) inhibitor avelumab with paclitaxel plus ramucirumab appears to be efficacious and safe in the second-line treatment of metastatic esophagogastric adenocarcinoma, as shown in the phase II nonrandomized RAP trial.

Low-dose calcium supplementation during pregnancy was noninferior to standard high-dose supplementation in preventing the risk of pre-eclampsia, according to two randomized clinical trials conducted in India and Tanzania.

Children who undergo cataract surgery appear to be at risk of having glaucoma later in life, according to a study.

In the treatment of older patients with nonvalvular atrial fibrillation (AF) who are considered ineligible for oral anticoagulants at the recommended therapeutic strength or the approved doses, the use of low-dose edoxaban helps reduce the risk of stroke or systemic embolism regardless of body weight, although this benefit comes with a slightly higher major bleeding events, according to the subgroup analysis of the phase III ELDERCARE‐AF trial.